Nav: Home

RCSI begins clinical trial for potential drug therapy for severe COVID-19 infection

June 29, 2020

Clinician scientists at RCSI University of Medicine and Health Sciences have begun a clinical trial of a promising therapy for critically ill COVID-19 patients in intensive care.

In a paper published in the American Journal of Respiratory and Critical Care Medicine, the team, led by RCSI Professors Gerry McElvaney and Ger Curley, describe changes in the body's normal inflammatory response in patients infected with COVID-19, in particular among those who require admission to intensive care.

The team has begun a randomised double blind placebo controlled clinical trial of alpha-1-antitrypsin to treat critically ill patients mechanically ventilated in ICU with COVID-19 associated Acute Respiratory Distress Syndrome. Alpha-1-antitrypsin is a naturally occurring human protein produced by the liver and released into the bloodstream which normally acts to protect the lungs from the destructive actions of common illnesses.

RCSI Professor of Medicine Prof. Gerry McElvaney said: "As of late June, more than 9.5 million laboratory-confirmed cases of COVID-19 have been documented globally, with over 490,000 deaths. These numbers continue to grow substantially. In Beaumont Hospital, we have had over 500 patients admitted to the hospital, and nearly 50 patients requiring admission to intensive care.

"The current management of severe COVID-19 remains supportive, focusing on supplemental oxygen and ventilator support in the event of acute respiratory failure. Despite the implications for global health, the inflammatory characteristics of patients with COVID-19 are not yet fully understood. A greater understanding of how the body's inflammatory mechanisms are impacted upon by COVID-19 could open the door to several potential therapies including antiviral medications and targeted immune-modulators such as alpha-1-antitrypsin."

Prof. Ger Curley, RCSI Professor of Anaesthesia and Critical Care and Consultant in Anaesthesia and Intensive Care in Beaumont Hospital explained that "we know from in-hospital studies that many COVID-19 patients in ICU develop severe inflammation throughout the body with a disproportionately high rate of progression to acute respiratory distress syndrome, acute renal failure, shock and heart arrhythmia."

In a collaboration between the Departments of Medicine and Critical Care and Anaesthesia, a team of clinician scientists led by Prof. McElvaney and Prof. Curley sought to ascertain the type of inflammation affecting the COVID-19 patient in ICU, and to determine whether there was a relationship between this type of inflammation and the need for intubation and mechanical ventilation.

The study showed that a number of highly inflamed proteins were all increased in infected patients compared to healthy controls. There was also a difference in the profiles of patients in ICU and those who were infected but stable.

Prof. Curley explained, however, that the most unanticipated differentiating factor between patients with stable and severe disease was not the degree of increase in inflammatory proteins, but rather the relative decrease in levels of an anti-inflammatory protein which indicates that the patients' anti-inflammatory mechanisms were failing.

"This finding suggests to us that a therapy which augments the body's own inflammation resolving mechanisms might have a positive impact. Alpha-1 protects the airway from damage during acute pulmonary infection. It is also a potent anti-inflammatory and acts to protect the immune system. Of particular relevance to COVID-19, it has been shown to modulate the production and activity of several key pro-inflammatory proteins", explained Prof. Curley.

"We are confident that this clinical trial will demonstrate the potential for Alpha-1 to improve the outcomes for patients with the most severe COVID-19 induced respiratory difficulties."

This is the first Investigational Medicine Product trial to be approved in Ireland to test a therapy to treat COVID19. The trial is being sponsored by RCSI University of Medicine and Health Sciences and is coordinated by the RCSI Clinical Research Centre. Beaumont Hospital is the first site to recruit patients and other sites in Ireland will also participate. This investigator initiated study benefited from generous support from Grifols, a Barcelona-based multinational healthcare company and a leading global producer of plasma-derived medicines, which provided access to the alpha1-proteinase inhibitor study drug.

Ranked number one globally for Good Health and Well-being in the Times Higher Education (THE) University Impact Rankings 2020, RCSI University of Medicine and Health Sciences is an international not-for-profit university, with its headquarters in Dublin.

RCSI is exclusively focused on education and research to drive improvements in human health worldwide. It is among the top 250 universities worldwide in the THE World University Rankings (2020) and its research is ranked first in Ireland for citations. RCSI has been awarded Athena Swan Bronze accreditation for positive gender practice in higher education.
-end-


RCSI

Related Inflammation Articles:

A protein that controls inflammation
A study by the research team of Prof. Geert van Loo (VIB-UGent Center for Inflammation Research) has unraveled a critical molecular mechanism behind autoimmune and inflammatory diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis.
Inflammation in the brain linked to several forms of dementia
Inflammation in the brain may be more widely implicated in dementias than was previously thought, suggests new research from the University of Cambridge.
Social isolation could cause physical inflammation
Social isolation could be associated with increased inflammation in the body new research from the University of Surrey and Brunel University London has found.
Hydrogels control inflammation to help healing
Researchers test a sampling of synthetic, biocompatible hydrogels to see how tuning them influences the body's inflammatory response.
Why beta-blockers cause skin inflammation
Beta-blockers are often used to treat high blood pressure and other cardiovascular diseases.
How do ketogenic diets affect skin inflammation?
Not all fats are equal in how they affect our skin, according to a new study in the Journal of Investigative Dermatology, published by Elsevier.
The 'inflammation' of opioid use
New research correlates inflammation in the brain and gut to negative emotional state during opioid withdrawal.
Using a common anticonvulsant to counteract inflammation
The interaction between a chromosomal protein called HMGB1 and a cellular receptor called RAGE is known to trigger inflammation.
The inflammation connection
New biological findings point towards a new avenue for the development of anti-inflammatory drugs.
Stopping inflammation from becoming chronic
An international research team led by Friedrich Schiller University in Jena has developed a highly sensitive cell model to study the complex effects -- and side effects -- of anti-inflammatory drugs, with the ultimate aim of preventing chronic inflammation.
More Inflammation News and Inflammation Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.